IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]
Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. Onco Targets Ther. 2020;13:9721–9730.
The authors have advised due to an error at the time of figure assembly, Figure 4 on page 9728 is incorrect. The correct Figure 4 is shown below.
The authors apologize for this error and advise it does not affect the results of the paper.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]